

·研究论文 ·

## 对氯苯乙酮肟醚衍生物的合成及生物活性

许 艳<sup>2</sup>, 袁莉萍<sup>\*1</sup>, 曹 琪<sup>1</sup>, 倪长春<sup>1</sup>,  
沈 宙<sup>1</sup>, 陈 亮<sup>1</sup>, 张一宾<sup>1</sup>

(1. 上海市农药研究所, 上海 200032; 2. 华东理工大学 药学院, 上海 200237)

**摘要:**为寻找高活性的新农药化合物,通过2取代氨基-1对氯苯乙酮-1肟与卤代烃反应,设计并合成了35个对氯苯乙酮肟醚衍生物,其结构均经核磁共振氢谱和元素分析确证。初步的生物活性测定结果表明,该类化合物具有一定的杀虫、抑菌及除草活性,其中C<sub>9</sub>、C<sub>12</sub>在500 mg/L时对蚜虫*Aphis craccivaora*的致死率达到100%;C<sub>10</sub>、C<sub>12</sub>、C<sub>15</sub>和C<sub>23</sub>在1 000 mg/L时对朱砂叶螨*Tetranychus cinabarinus*的致死率达到100%;C<sub>29</sub>、C<sub>30</sub>和C<sub>31</sub>在500 mg/L时对黄瓜白粉病菌*Sphaerotheca fuliginea*的抑制率达到95%以上;C<sub>29</sub>、C<sub>30</sub>、C<sub>33</sub>和C<sub>35</sub>在100 mg/L时对马唐*Digitaria sanguinalis*的抑制率达到90%以上。

**关键词:**苯乙酮肟;合成;肟醚;生物活性

中图分类号:O623.542

文献标志码:A

文章编号:1008-7303(2007)01-0019-06

## Synthesis and Bioactivity of 4-ChlorophenylM ethyl Ketone Oxime Ether Derivatives

XU Yan<sup>2</sup>, YUAN Liping<sup>\*1</sup>, CAO Jin<sup>1</sup>, NI Chang-chun<sup>1</sup>,  
SHEN Zhou<sup>1</sup>, CHEN Liang<sup>1</sup>, ZHANG Yi-bin<sup>1</sup>

(1. Shanghai Pesticide Research Institute, Shanghai 200032, China;

2. East China University of Science and Technology, Pharmaceutical Institute, Shanghai 200237, China)

**Abstract:** In search of novel pesticide leading compound with high bioactivity, thirty-five 4-chlorophenyl methyl ketone oxime ether derivatives were designed and synthesized by the reaction of 2-substituted amino 4-chlorophenyl methyl ketone oxime with halohydrocarbon. The structure of all novel compounds was confirmed by <sup>1</sup>H NMR and elemental analysis. Preliminary bioassays showed that some compounds exhibited certain insecticidal and herbicidal activities. The mortality of C<sub>9</sub>, C<sub>12</sub> to *Aphis craccivaora* reached 100% at the concentration of 500 mg/L. The mortality of C<sub>10</sub>, C<sub>12</sub>, C<sub>15</sub> and C<sub>23</sub> to *Tetranychus cinabarinus* reached 100% at 1 000 mg/L. The inhibition rate of C<sub>29</sub>, C<sub>30</sub> and C<sub>31</sub> to *Sphaerotheca fuliginea* was over 95% at the concentration of 500 mg/L. The inhibition rate of C<sub>29</sub>, C<sub>30</sub>, C<sub>33</sub> and C<sub>35</sub> to *Digitaria sanguinalis* was over 90% at the concentration of 100 mg/L.


**Key words:** phenyl methyl ketone oxime; synthesis; oxime ether; bioactivity

收稿日期:2006-12-13;修回日期:2007-01-20.

作者简介:许艳(1982-),女,湖北人,硕士研究生; \*通讯作者:袁莉萍(1964-),女,上海人,教授级高级工程师,主要从事新农药创制研究工作。联系电话:021-64644052; E-mail: spric@online.sh.cn

基金项目:国家重点基础研究发展计划("973"计划)项目(2003CB114401).

芳基烷基酮肟醚因具有相当的杀虫、杀菌、除草、抗植物病毒活性而令人关注<sup>[1]</sup>。肟醚结构则已成为新农药研制开发中的常用基团,此类结构化合物大多具有高效、低毒、低残留等优点<sup>[2,3]</sup>。如20世纪80年代由汽巴嘉基公司开发的除草剂肟草安(fluxofenim)、杀菌剂啶斑肟(pyrifenoxy)<sup>[1,2]</sup>等。



## 1 合成实验

### 1.1 仪器及试剂

Bruker AC300型核磁共振仪( $\text{CDCl}_3$ 为溶剂,TMS为内标);WRS-1A型数字熔点仪;2W型阿贝折射仪。所用的试剂均为化学纯或者分析纯。

### 1.2 中间体A、B的制备

按文献[7]方法合成。

### 1.3 目标化合物C的合成<sup>[7,8]</sup>

以O-正丙基-1-(4氯苯基)-2-(N,N二正丁基氨基)-1乙酮肟(C<sub>9</sub>)的合成为例。在100 mL的

近年来有不少新的苯乙酮肟类衍生物的研究报道<sup>[4~6]</sup>,这一类化合物对作物常见病害如白粉病、炭疽病、菌核病等具有一定的防治效果<sup>[5]</sup>。笔者设计合成了含对氯苯乙酮肟结构的化合物,并进行了杀虫、杀菌和除草活性筛选,从中发现了一些具有一定活性的化合物。合成路线如下:

三口烧瓶中加入0.89 g(3 mmol)1-(4氯苯基)-2-(N,N二正丁基氨基)-1乙酮肟,0.61 g(5 mmol)溴代正丙烷,0.20 g(5 mmol)氢氧化钠,0.2 g四丁基溴化铵(TBAB)和50 mL丙酮,40~50℃下搅拌5 h。减压蒸去溶剂,残余物中加入二氯甲烷,有机层经水洗,无水硫酸镁干燥后减压脱溶,得到黄色粘稠液。经柱层析(石油醚-乙酸乙酯=6:1,体积比)分离提纯,得到淡黄色液体0.55 g。

同法合成其他目标化合物,其物理常数及元素分析数据见表1,<sup>1</sup>H NMR数据见表2。

Table 1 Physical and elemental analytical data of compounds C

Compd	NR <sup>1</sup> R <sup>2</sup>	R <sup>3</sup>	$n_D^{25}$ or Mp /	Yield (%)	Elemental analysis (Calcd, %)		
					C	H	N
C <sub>1</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	CH <sub>2</sub> =CHCH <sub>2</sub>	1.528 9	57.5	58.31 (58.10)	6.35 (6.38)	10.63 (10.42)
C <sub>2</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	n-C <sub>3</sub> H <sub>7</sub>	1.516 5	47.8	57.69 (57.67)	7.12 (7.07)	10.22 (10.35)
C <sub>3</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	i-C <sub>3</sub> H <sub>7</sub>	60.1~61.3	76.5	57.75 (57.67)	7.15 (7.07)	10.24 (10.35)
C <sub>4</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	sec-C <sub>4</sub> H <sub>9</sub>	1.510 8	63.8	59.16 (59.05)	7.51 (7.43)	9.59 (9.84)
C <sub>5</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	i-C <sub>4</sub> H <sub>9</sub>	1.513 8	72.5	59.26 (59.05)	7.35 (7.43)	9.68 (9.84)
C <sub>6</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	p-ClC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	68.3~69.2	50.1	57.87 (57.80)	5.08 (5.14)	7.82 (7.93)
C <sub>7</sub>	N(OCH <sub>3</sub> )CH <sub>3</sub>	i-C <sub>5</sub> H <sub>11</sub>	1.510 7	39.2	60.45 (60.29)	7.88 (7.76)	9.27 (9.38)
C <sub>8</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	CH <sub>2</sub> =CHCH <sub>2</sub>	1.515 0	81.6	67.55 (67.74)	8.49 (8.68)	8.14 (8.32)
C <sub>9</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	n-C <sub>3</sub> H <sub>7</sub>	1.506 5	55.0	67.56 (67.33)	9.36 (9.22)	8.33 (8.27)
C <sub>10</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	i-C <sub>3</sub> H <sub>7</sub>	1.503 2	74.2	67.56 (67.33)	9.25 (9.22)	8.35 (8.27)
C <sub>11</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	sec-C <sub>4</sub> H <sub>9</sub>	1.503 4	75.4	68.21 (68.06)	9.26 (9.42)	7.86 (7.94)
C <sub>12</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	i-C <sub>4</sub> H <sub>9</sub>	1.502 0	60.8	68.26 (68.06)	9.22 (9.42)	7.85 (7.94)
C <sub>13</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	i-C <sub>5</sub> H <sub>11</sub>	1.501 9	73.6	68.55 (68.73)	9.53 (9.61)	7.56 (7.63)
C <sub>14</sub>	N(n-C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>	p-ClC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	1.545 9	59.3	65.84 (65.55)	7.29 (7.18)	6.42 (6.65)

Continued

Compd	NR <sup>1</sup> R <sup>2</sup>	R <sup>3</sup>	n <sub>D</sub> <sup>25</sup> or Mp /	Yield (%)	Elemental analysis (Calcd, %)		
					C	H	N
C <sub>15</sub>	Piperidinyl	CH <sub>2</sub> =CHCH <sub>2</sub>	1. 544 0	69. 5	66. 54 (65. 63)	7. 69 (7. 23)	9. 27 (9. 57)
C <sub>16</sub>	Piperidinyl	n-C <sub>3</sub> H <sub>7</sub>	1. 533 5	70. 2	65. 27 (65. 18)	7. 64 (7. 86)	9. 66 (9. 50)
C <sub>17</sub>	Piperidinyl	i-C <sub>3</sub> H <sub>7</sub>	1. 530 9	62. 0	65. 39 (65. 18)	7. 89 (7. 86)	9. 42 (9. 50)
C <sub>18</sub>	Piperidinyl	sec-C <sub>4</sub> H <sub>9</sub>	1. 528 0	59. 3	66. 26 (66. 11)	8. 33 (8. 16)	8. 94 (9. 07)
C <sub>19</sub>	Piperidinyl	i-C <sub>4</sub> H <sub>9</sub>	1. 528 5	71. 2	66. 32 (66. 11)	8. 21 (8. 16)	9. 14 (9. 07)
C <sub>20</sub>	Piperidinyl	i-C <sub>5</sub> H <sub>11</sub>	1. 523 1	60. 3	66. 98 (66. 96)	8. 32 (8. 43)	8. 95 (8. 68)
C <sub>21</sub>	Piperidinyl	p-CIC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	1. 570 5	50. 9	63. 44 (63. 67)	5. 96 (5. 88)	7. 38 (7. 42)
C <sub>22</sub>	Morpholinyl	CH <sub>2</sub> =CHCH <sub>2</sub>	53. 9 ~ 55. 1	67. 3	61. 18 (61. 12)	6. 30 (6. 50)	9. 21 (9. 50)
C <sub>23</sub>	Morpholinyl	n-C <sub>3</sub> H <sub>7</sub>	1. 534 0	73. 2	60. 85 (60. 70)	7. 16 (7. 13)	9. 25 (9. 44)
C <sub>24</sub>	Morpholinyl	i-C <sub>3</sub> H <sub>7</sub>	63. 8 ~ 64. 1	83. 4	60. 55 (60. 70)	7. 23 (7. 13)	9. 51 (9. 44)
C <sub>25</sub>	Morpholinyl	sec-C <sub>4</sub> H <sub>9</sub>	1. 528 5	71. 0	61. 72 (61. 83)	7. 66 (7. 46)	9. 14 (9. 01)
C <sub>26</sub>	Morpholinyl	i-C <sub>4</sub> H <sub>9</sub>	36. 0 ~ 37. 1	69. 8	61. 72 (61. 83)	7. 53 (7. 46)	9. 20 (9. 01)
C <sub>27</sub>	Morpholinyl	i-C <sub>5</sub> H <sub>11</sub>	1. 525 0	42. 4	62. 74 (62. 86)	7. 86 (7. 76)	8. 91 (8. 62)
C <sub>28</sub>	Morpholinyl	p-CIC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	41. 6 ~ 42. 3	81. 2	60. 23 (60. 17)	5. 16 (5. 32)	7. 48 (7. 39)
C <sub>29</sub>	Indazol	n-C <sub>3</sub> H <sub>7</sub>	1. 561 8	86. 3	60. 63 (60. 54)	5. 74 (5. 81)	15. 36 (15. 13)
C <sub>30</sub>	Indazol	i-C <sub>3</sub> H <sub>7</sub>	75. 0 ~ 78. 3	76. 8	60. 36 (60. 54)	5. 66 (5. 81)	15. 30 (15. 13)
C <sub>31</sub>	Indazol	sec-C <sub>4</sub> H <sub>9</sub>	1. 542 0	50. 1	61. 65 (61. 75)	6. 34 (6. 22)	14. 29 (14. 40)
C <sub>32</sub>	Indazol	i-C <sub>4</sub> H <sub>9</sub>	85. 9 ~ 87. 5	65. 2	61. 72 (61. 75)	6. 35 (6. 22)	14. 28 (14. 40)
C <sub>33</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>2</sub> =CHCH <sub>2</sub>	1. 534 8	55. 4	61. 60 (61. 78)	6. 86 (6. 78)	11. 15 (11. 08)
C <sub>34</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	n-C <sub>3</sub> H <sub>7</sub>	1. 524 5	64. 7	61. 37 (61. 29)	7. 59 (7. 52)	11. 26 (11. 00)
C <sub>35</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	i-C <sub>3</sub> H <sub>7</sub>	51. 7 ~ 52. 4	57. 4	61. 16 (61. 29)	7. 64 (7. 52)	11. 25 (11. 00)

Table 2 <sup>1</sup>H NMR data of compounds C

Compd	<sup>1</sup> H NMR (CDCl <sub>3</sub> /TMS),
C <sub>1</sub>	2. 61 (s, 3H, NCH <sub>3</sub> ), 3. 34 (s, 3H, OCH <sub>3</sub> ), 3. 66 (s, 2H, NCH <sub>2</sub> ), 4. 62 (d, 2H, J = 5. 60 Hz, OCH <sub>2</sub> ), 5. 16 ~ 5. 29 (m, 2H, = CH <sub>2</sub> ), 5. 91 ~ 6. 10 (m, 1H, = CH), 7. 37 (d, 2H, J = 8. 68 Hz, A tH-2, 6), 7. 57 (d, 2H, J = 8. 68 Hz, A tH-3, 5)
C <sub>2</sub>	0. 93 (t, 3H, CH <sub>3</sub> ), 1. 68 (m, 2H, CH <sub>2</sub> ), 2. 59 (s, 3H, NCH <sub>3</sub> ), 3. 35 (s, 3H, OCH <sub>3</sub> ), 3. 65 (s, 2H, NCH <sub>2</sub> ), 4. 06 (t, 2H, OCH <sub>2</sub> ), 7. 35 (d, 2H, J = 8. 82 Hz, A tH-2, 6), 7. 57 (d, 2H, J = 8. 82 Hz, A tH-3, 5)
C <sub>3</sub>	1. 23 (d, 6H, J = 6. 00 Hz, 2CH <sub>3</sub> ), 2. 60 (s, 3H, NCH <sub>3</sub> ), 3. 35 (s, 3H, OCH <sub>3</sub> ), 3. 66 (s, 2H, NCH <sub>2</sub> ), 4. 35 ~ 4. 48 (m, 1H, CH), 7. 34 (d, 2H, J = 8. 44 Hz, A tH-2, 6), 7. 62 (d, 2H, J = 8. 44 Hz, A tH-3, 5)
C <sub>4</sub>	0. 93 (t, 3H, CH <sub>3</sub> ), 1. 26 (d, 3H, J = 6. 05 Hz, CH <sub>3</sub> ), 1. 49 ~ 1. 73 (m, 2H, CH <sub>2</sub> ), 2. 62 (s, 3H, NCH <sub>3</sub> ), 3. 39 (s, 3H, OCH <sub>3</sub> ), 3. 69 (s, 2H, NCH <sub>2</sub> ), 4. 19 ~ 4. 29 (m, 1H, CH), 7. 37 (d, 2H, J = 8. 45 Hz, A tH-2, 6), 7. 64 (d, 2H, J = 8. 45 Hz, A tH-3, 5)
C <sub>5</sub>	0. 90 (d, 6H, J = 6. 86 Hz, 2CH <sub>3</sub> ), 1. 92 ~ 2. 06 (m, 1H, CH), 2. 59 (s, 3H, NCH <sub>3</sub> ), 3. 35 (s, 3H, OCH <sub>3</sub> ), 3. 65 (s, 2H, NCH <sub>2</sub> ), 3. 88 (d, 2H, J = 6. 86 Hz, OCH <sub>2</sub> ), 7. 35 (d, 2H, J = 8. 50 Hz, A tH-2, 6), 7. 57 (d, 2H, J = 8. 50 Hz, A tH-3, 5)
C <sub>6</sub>	2. 57 (s, 3H, NCH <sub>3</sub> ), 3. 30 (s, 3H, OCH <sub>3</sub> ), 3. 64 (s, 2H, NCH <sub>2</sub> ), 5. 10 (s, 2H, OCH <sub>2</sub> ), 7. 30 (d, 2H, J = 8. 78 Hz, A tH-2, 6), 7. 34 (d, 2H, J = 8. 60 Hz, A tH-2, 6), 7. 37 (d, 2H, J = 8. 60 Hz, A tH-3, 5), 7. 64 (d, 2H, J = 8. 78 Hz, A tH-3, 5)
C <sub>7</sub>	0. 90 (d, 6H, J = 6. 34 Hz, 2CH <sub>3</sub> ), 1. 54 (t, 2H, CH <sub>2</sub> ), 1. 58 ~ 1. 60 (m, 1H, CH), 2. 59 (s, 3H, NCH <sub>3</sub> ), 3. 35 (s, 3H, OCH <sub>3</sub> ), 3. 65 (s, 2H, NCH <sub>2</sub> ), 3. 88 (d, 2H, J = 6. 86 Hz, OCH <sub>2</sub> ), 7. 35 (d, 2H, J = 8. 54 Hz, A tH-2, 6), 7. 57 (d, 2H, J = 8. 54 Hz, A tH-3, 5)
C <sub>8</sub>	0. 86 (t, 6H, 2CH <sub>3</sub> ), 1. 14 ~ 1. 28 (m, 4H, 2CH <sub>2</sub> ), 1. 32 ~ 1. 41 (m, 4H, 2CH <sub>2</sub> ), 2. 43 (t, 4H, 2NCH <sub>2</sub> ), 3. 39 (s, 2H, NCH <sub>2</sub> ), 4. 59 (d, 2H, J = 5. 60 Hz, OCH <sub>2</sub> ), 5. 18 ~ 5. 30 (m, 2H, = CH <sub>2</sub> ), 5. 94 ~ 6. 03 (m, 1H, = CH), 7. 34 (d, 2H, J = 8. 50 Hz, A tH-2, 6), 7. 56 (d, 2H, J = 8. 50 Hz, A tH-3, 5)
C <sub>9</sub>	0. 84 ~ 0. 95 (m, 9H, 3CH <sub>3</sub> ), 1. 15 ~ 1. 27 (m, 4H, 2CH <sub>2</sub> ), 1. 33 ~ 1. 44 (m, 4H, 2CH <sub>2</sub> ), 1. 66 ~ 1. 73 (m, 2H, CH <sub>2</sub> ), 2. 45 (t, 4H, 2NCH <sub>2</sub> ), 3. 41 (s, 2H, NCH <sub>2</sub> ), 4. 05 (t, 2H, OCH <sub>2</sub> ), 7. 35 (d, 2H, J = 8. 40 Hz, A tH-2, 6), 7. 57 (d, 2H, J = 8. 40 Hz, A tH-3, 5)

Continued

Compd	<sup>1</sup> HNMR (CDCl <sub>3</sub> /TMS),
C <sub>10</sub>	0. 86 (t, 6H, 2CH <sub>3</sub> ) , 1. 14 ~ 1. 22 (m, 4H, 2CH <sub>2</sub> ) , 1. 29 (d, 6H, J = 6. 30 Hz, 2CH <sub>3</sub> ) , 1. 34 ~ 1. 44 (m, 4H, 2CH <sub>2</sub> ) , 2. 45 (t, 4H, 2NCH <sub>2</sub> ) , 3. 41 (s, 2H, NCH <sub>2</sub> ) , 4. 34 ~ 4. 42 (m, 1H, OCH) , 7. 33 (d, 2H, J = 8. 70 Hz, A tH-2, 6) , 7. 61 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>11</sub>	0. 85 ~ 0. 97 (m, 9H, 3CH <sub>3</sub> ) , 1. 18 ~ 1. 25 (m, 4H, 2CH <sub>2</sub> ) , 1. 23 (d, 3H, J = 8. 40 Hz, CH <sub>3</sub> ) , 1. 34 ~ 1. 44 (m, 4H, 2CH <sub>2</sub> ) , 1. 53 ~ 1. 68 (m, 2H, CH <sub>2</sub> ) , 2. 44 (t, 4H, 2NCH <sub>2</sub> ) , 3. 41 (s, 2H, NCH <sub>2</sub> ) , 4. 17 ~ 4. 19 (m, 1H, OCH) , 7. 34 (d, 2H, J = 8. 40 Hz, A tH-2, 6) , 7. 62 (d, 2H, J = 8. 40 Hz, A tH-3, 5)
C <sub>12</sub>	0. 84 ~ 0. 92 (m, 12H, 4CH <sub>3</sub> ) , 1. 16 ~ 1. 19 (m, 4H, 2CH <sub>2</sub> ) , 1. 21 ~ 1. 26 (m, 4H, 2CH <sub>2</sub> ) , 1. 98 ~ 2. 03 (m, 1H, CH) , 2. 43 (t, 4H, 2NCH <sub>2</sub> ) , 3. 38 (s, 2H, NCH <sub>2</sub> ) , 3. 85 (d, 2H, J = 7. 20 Hz, OCH <sub>2</sub> ) , 7. 33 (d, 2H, J = 8. 70 Hz, A tH-2, 6) , 7. 57 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>13</sub>	0. 84 ~ 0. 94 (m, 12H, 4CH <sub>3</sub> ) , 1. 15 ~ 1. 27 (m, 4H, 2CH <sub>2</sub> ) , 1. 33 ~ 1. 44 (m, 4H, 2CH <sub>2</sub> ) , 1. 55 (t, 2H, CH <sub>2</sub> ) , 1. 64 ~ 1. 71 (m, 1H, CH) , 2. 43 (t, 4H, 2NCH <sub>2</sub> ) , 3. 38 (s, 2H, NCH <sub>2</sub> ) , 4. 13 (t, 2H, OCH <sub>2</sub> ) , 7. 33 (d, 2H, J = 8. 70 Hz, A tH-2, 6) , 7. 56 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>14</sub>	0. 87 (t, 6H, 2CH <sub>3</sub> ) , 1. 12 ~ 1. 24 (m, 4H, 2CH <sub>2</sub> ) , 1. 30 ~ 1. 40 (m, 4H, 2CH <sub>2</sub> ) , 2. 41 (t, 4H, 2NCH <sub>2</sub> ) , 3. 41 (s, 2H, NCH <sub>2</sub> ) , 5. 10 (s, 2H, OCH <sub>2</sub> ) , 7. 26 ~ 7. 38 (m, 6H, A tH-2, 6, 2, 6, 3, 5) , 7. 55 (d, 2H, J = 8. 40 Hz, A tH-3, 5)
C <sub>15</sub>	1. 39 ~ 1. 52 (m, 6H, 3CH <sub>2</sub> ) , 2. 41 (t, 4H, 2NCH <sub>2</sub> ) , 3. 28 (s, 2H, NCH <sub>2</sub> ) , 4. 57 (d, 2H, J = 5. 40 Hz, OCH <sub>2</sub> ) , 5. 16 ~ 5. 28 (m, 2H, =CH <sub>2</sub> ) , 5. 89 ~ 6. 05 (m, 1H, =CH) , 7. 30 (d, 2H, J = 8. 80 Hz, A tH-2, 6) , 7. 57 (d, 2H, J = 8. 80 Hz, A tH-3, 5)
C <sub>16</sub>	0. 92 (t, 3H, CH <sub>3</sub> ) , 1. 37 ~ 1. 57 (m, 6H, 3CH <sub>2</sub> ) , 1. 62 ~ 1. 74 (m, 2H, CH <sub>2</sub> ) , 2. 43 (t, 4H, 2NCH <sub>2</sub> ) , 3. 30 (s, 2H, NCH <sub>2</sub> ) , 4. 05 (t, 2H, OCH <sub>2</sub> ) , 7. 35 (d, 2H, J = 8. 70 Hz, A tH-2, 6) , 7. 61 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>17</sub>	1. 24 (d, 6H, J = 6. 30 Hz, 2CH <sub>3</sub> ) , 1. 41 ~ 1. 57 (m, 6H, 3CH <sub>2</sub> ) , 2. 44 (t, 4H, 2NCH <sub>2</sub> ) , 3. 32 (s, 2H, NCH <sub>2</sub> ) , 4. 36 ~ 4. 41 (m, 1H, OCH) , 7. 33 (d, 2H, J = 8. 70 Hz, A tH ~ 2, 6) , 7. 65 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>18</sub>	0. 91 (t, 3H, CH <sub>3</sub> ) , 1. 21 (d, 3H, J = 6. 00 Hz, CH <sub>3</sub> ) , 1. 41 ~ 1. 58 (m, 6H, 3CH <sub>2</sub> ) , 1. 62 ~ 1. 67 (m, 2H, CH <sub>2</sub> ) , 2. 44 (t, 4H, 2NCH <sub>2</sub> ) , 3. 33 (s, 2H, NCH <sub>2</sub> ) , 4. 15 ~ 4. 21 (m, 1H, OCH) , 7. 35 (d, 2H, J = 8. 70 Hz, A tH-2, 6) , 7. 65 (d, 2H, J = 8. 70 Hz, A tH-3, 5)
C <sub>19</sub>	0. 90 (d, 6H, J = 6. 60 Hz, 2CH <sub>3</sub> ) , 1. 41 ~ 1. 57 (m, 6H, 3CH <sub>2</sub> ) , 1. 96 ~ 2. 01 (m, 1H, CH) , 2. 44 (t, 4H, 2NCH <sub>2</sub> ) , 3. 33 (s, 2H, NCH <sub>2</sub> ) , 3. 86 (d, 2H, J = 6. 60 Hz, OCH <sub>2</sub> ) , 7. 35 (d, 2H, J = 8. 40 Hz, A tH-2, 6) , 7. 59 (d, 2H, J = 8. 40 Hz, A tH-3, 5)
C <sub>20</sub>	0. 91 (d, 6H, J = 6. 30 Hz, 2CH <sub>3</sub> ) , 1. 38 ~ 1. 45 (m, 2H, CH <sub>2</sub> ) , 1. 51 ~ 1. 58 (m, 6H, 3CH <sub>2</sub> ) , 1. 60 ~ 1. 69 (m, 1H, CH) , 2. 44 (t, 4H, 2NCH <sub>2</sub> ) , 3. 31 (s, 2H, NCH <sub>2</sub> ) , 4. 12 (t, 2H, OCH <sub>2</sub> ) , 7. 34 (d, 2H, J = 8. 60 Hz, A tH-2, 6) , 7. 59 (d, 2H, J = 8. 60 Hz, A tH-3, 5)
C <sub>21</sub>	1. 41 ~ 1. 56 (m, 6H, 3CH <sub>2</sub> ) , 2. 39 (t, 4H, 2NCH <sub>2</sub> ) , 3. 29 (s, 2H, NCH <sub>2</sub> ) , 5. 09 (s, 2H, OCH <sub>2</sub> ) , 7. 23 ~ 7. 37 (m, 6H, A tH-2, 6, 2, 6, 3, 5) , 7. 55 (d, 2H, J = 8. 40 Hz, A tH-3, 5)
C <sub>22</sub>	2. 50 (t, 4H, 2NCH <sub>2</sub> ) , 3. 33 (s, 2H, NCH <sub>2</sub> ) , 3. 66 (t, 4H, 2OCH <sub>2</sub> ) , 4. 59 (d, 2H, J = 5. 40 Hz, OCH <sub>2</sub> ) , 5. 15 ~ 5. 30 (m, 2H, =CH <sub>2</sub> ) , 5. 87 ~ 6. 03 (m, 1H, =CH) , 7. 35 (d, 2H, J = 8. 77 Hz, A tH-2, 6) , 7. 59 (d, 2H, J = 8. 77 Hz, A tH-3, 5)
C <sub>23</sub>	0. 91 (t, 3H, CH <sub>3</sub> ) , 1. 61 ~ 1. 72 (m, 2H, CH <sub>2</sub> ) , 2. 49 (t, 4H, 2NCH <sub>2</sub> ) , 3. 32 (s, 2H, NCH <sub>2</sub> ) , 3. 66 (t, 4H, 2OCH <sub>2</sub> ) , 4. 04 (t, 2H, OCH <sub>2</sub> ) , 7. 35 (d, 2H, J = 8. 54 Hz, A tH ~ 2, 6) , 7. 60 (d, 2H, J = 8. 54 Hz, A tH-3, 5)
C <sub>24</sub>	1. 28 (d, 6H, J = 6. 20 Hz, 2CH <sub>3</sub> ) , 2. 55 (t, 4H, 2NCH <sub>2</sub> ) , 3. 38 (s, 2H, NCH <sub>2</sub> ) , 3. 72 (t, 4H, 2OCH <sub>2</sub> ) , 4. 39 ~ 4. 46 (m, 1H, CH) , 7. 39 (d, 2H, J = 8. 60 Hz, A tH-2, 6) , 7. 69 (d, 2H, J = 8. 60 Hz, A tH-3, 5)
C <sub>25</sub>	0. 89 (t, 3H, CH <sub>3</sub> ) , 1. 20 (d, 3H, J = 6. 20 Hz, CH <sub>3</sub> ) , 1. 43 ~ 1. 70 (m, 2H, CH <sub>2</sub> ) , 2. 49 (t, 4H, 2NCH <sub>2</sub> ) , 3. 33 (s, 2H, NCH <sub>2</sub> ) , 3. 66 (t, 4H, 2OCH <sub>2</sub> ) , 3. 87 (d, 2H, J = 6. 40 Hz, OCH <sub>2</sub> ) , 4. 13 ~ 4. 22 (m, 1H, CH) , 7. 33 (d, 2H, J = 8. 57 Hz, A tH-2, 6) , 7. 65 (d, 2H, J = 8. 57 Hz, A tH-3, 5)
C <sub>26</sub>	0. 90 (d, 6H, J = 6. 80 Hz, 2CH <sub>3</sub> ) , 1. 95 ~ 2. 01 (m, 1H, CH) , 2. 51 (t, 4H, 2NCH <sub>2</sub> ) , 3. 35 (s, 2H, NCH <sub>2</sub> ) , 3. 68 (t, 4H, 2OCH <sub>2</sub> ) , 3. 87 (d, 2H, J = 6. 40 Hz, OCH <sub>2</sub> ) , 7. 36 (d, 2H, J = 8. 26 Hz, A tH-2, 6) , 7. 60 (d, 2H, J = 8. 26 Hz, A tH-3, 5)
C <sub>27</sub>	0. 90 (d, 6H, J = 6. 20 Hz, 2CH <sub>3</sub> ) , 1. 53 (t, 2H, CH <sub>2</sub> ) , 1. 55 ~ 1. 59 (m, 1H, CH) , 2. 49 (t, 4H, 2NCH <sub>2</sub> ) , 3. 32 (s, 2H, NCH <sub>2</sub> ) , 3. 66 (t, 4H, 2OCH <sub>2</sub> ) , 4. 12 (t, 2H, OCH <sub>2</sub> ) , 7. 34 (d, 2H, J = 8. 52 Hz, A tH-2, 6) , 7. 59 (d, 2H, J = 8. 52 Hz, A tH-3, 5)
C <sub>28</sub>	2. 51 (t, 4H, 2NCH <sub>2</sub> ) , 3. 38 (s, 2H, NCH <sub>2</sub> ) , 3. 70 (t, 4H, 2OCH <sub>2</sub> ) , 5. 13 (s, 2H, OCH <sub>2</sub> ) , 7. 25 ~ 7. 33 (m, 4H, A tH-2, 6, 2, 6) , 7. 40 (d, 2H, J = 8. 70 Hz, A tH-3, 5) , 7. 59 (d, 2H, J = 8. 63 Hz, A tH-3, 5)

Continued

Compd	<sup>1</sup> HNMR ( $\text{CDCl}_3$ / TM S),
<b>C<sub>29</sub></b>	0. 97 (t, 3H, $\text{CH}_3$ ), 1. 71 ~ 1. 83 (m, 2H, $\text{CH}_2$ ), 4. 23 (t, 2H, $\text{OCH}_2$ ), 5. 15 (s, 2H, $\text{NCH}_2$ ), 6. 88 (s, 1H, in idazolyl-4), 6. 99 (s, 1H, in idazolyl-5), 7. 32 (d, 2H, $J = 8.70 \text{ Hz}$ , A tH-3, 5), 7. 48 (d, 2H, $J = 8.70 \text{ Hz}$ , A tH-2, 6), 7. 51 (s, 1H, in idazolyl-2)
<b>C<sub>30</sub></b>	1. 23 (d, 6H, $J = 6.00 \text{ Hz}$ , $2\text{CH}_3$ ), 4. 36 ~ 4. 45 (m, 1H, OCH), 4. 89 (s, 2H, $\text{NCH}_2$ ), 6. 86 (s, 1H, in idazolyl-4), 7. 00 (s, 1H, in idazolyl-5), 7. 22 (d, 2H, $J = 8.70 \text{ Hz}$ , A tH-3, 5), 7. 32 (d, 2H, $J = 8.70 \text{ Hz}$ , A tH-2, 6), 7. 40 (s, 1H, in idazolyl-2)
<b>C<sub>31</sub></b>	0. 94 (t, 3H, $\text{CH}_3$ ), 1. 29 (d, 3H, $J = 6.30 \text{ Hz}$ , $\text{CH}_3$ ), 1. 53 ~ 1. 80 (m, 2H, $\text{CH}_2$ ), 4. 31 ~ 4. 37 (m, 1H, OCH), 5. 15 (s, 2H, $\text{NCH}_2$ ), 6. 87 (s, 1H, in idazolyl-4), 6. 98 (s, 1H, in idazolyl-5), 7. 31 (d, 2H, $J = 8.40 \text{ Hz}$ , A tH-3, 5), 7. 52 (d, 2H, $J = 8.40 \text{ Hz}$ , A tH-2, 6), 7. 56 (s, 1H, in idazolyl-2)
<b>C<sub>32</sub></b>	0. 97 (d, 6H, $J = 6.60 \text{ Hz}$ , $2\text{CH}_3$ ), 2. 06 ~ 2. 10 (m, 1H, CH), 4. 07 (d, 2H, $J = 6.90 \text{ Hz}$ , $\text{OCH}_2$ ), 5. 21 (s, 2H, $\text{NCH}_2$ ), 6. 91 (s, 1H, in idazolyl-4), 7. 03 (s, 1H, in idazolyl-5), 7. 33 (d, 2H, $J = 8.40 \text{ Hz}$ , A tH-3, 5), 7. 52 (d, 2H, $J = 8.40 \text{ Hz}$ , A tH-2, 6), 7. 68 (s, 1H, in idazolyl-2)
<b>C<sub>33</sub></b>	2. 24 (s, 6H, $2\text{CH}_3$ ), 3. 29 (s, 2H, $\text{NCH}_2$ ), 4. 60 (d, 2H, $J = 5.40 \text{ Hz}$ , $\text{OCH}_2$ ), 5. 20 ~ 5. 28 (m, 2H, =CH <sub>2</sub> ), 5. 91 ~ 6. 10 (m, 1H, =CH), 7. 35 (d, 2H, $J = 8.55 \text{ Hz}$ , A tH-2, 6), 7. 55 (d, 2H, $J = 8.55 \text{ Hz}$ , A tH-3, 5)
<b>C<sub>34</sub></b>	0. 91 (t, 3H, $\text{CH}_3$ ), 1. 62 ~ 1. 73 (m, 2H, $\text{CH}_2$ ), 2. 24 (s, 6H, $2\text{CH}_3$ ), 3. 29 (s, 2H, $\text{NCH}_2$ ), 4. 05 (t, 2H, $\text{OCH}_2$ ), 7. 35 (d, 2H, $J = 8.47 \text{ Hz}$ , A tH-2, 6), 7. 55 (d, 2H, $J = 8.47 \text{ Hz}$ , A tH-3, 5)
<b>C<sub>35</sub></b>	1. 23 (d, 6H, $J = 6.20 \text{ Hz}$ , $2\text{CH}_3$ ), 2. 24 (s, 6H, $2\text{NCH}_3$ ), 3. 29 (s, 2H, $\text{NCH}_2$ ), 4. 32 ~ 4. 45 (m, 1H, CH), 7. 35 (d, 2H, $J = 8.55 \text{ Hz}$ , A tH-2, 6), 7. 60 (d, 2H, $J = 8.55 \text{ Hz}$ , A tH-3, 5)

## 2 生物活性测定

按《国家南方农药创制中心生测标准程序》进行。称取一定量药物,加入2%DMF使药物溶解,用无菌水稀释成1000 mg/L母液。然后再用无菌水稀释成500、250、125、100 mg/L系列浓度药液备用。

### 2.1 杀虫活性

2.1.1 杀蚜虫 *Aphis craccivaora* 活性 测试浓度为500 mg/L,重复3次,设空白对照。

2.1.2 杀螨 *Tetranychus cinnabarinus* 活性 测试浓度1000 mg/L,重复3次,设空白对照。

### 2.2 杀菌活性

采用活体盆栽法测试,测试对象为稻瘟病菌 *Piricularia oryzae*、水稻纹枯病菌 *Rhizoctonia solani*、黄瓜灰霉病菌 *Botrytis cinerea*、黄瓜白粉病菌 *Sphaerotheca fuliginea*、小麦赤霉病菌 *Gibberella zeae*、玉米小斑病菌 *Helminthosporium maydis*,测试浓度分别为500、250和125 mg/L,重复4次。设空白对照。

### 2.3 除草活性

采用平皿法,测试对象为稗草 *Echinochloa crusgalli* Link、高粱 *Sorghum vulgare* Pers.、马唐 *Digitaria sanguinalis*、苋菜 *Amaranthus tricolor* Linn.、黄瓜 *Cucumis sativus*、油菜 *Brassica albovariegata*,测试浓度为100 mg/L,重复3次。设空白对照。

## 3 结果与讨论

生物活性测定结果(表3)表明,所合成的部分化合物具有一定的杀虫活性。在500 mg/L时,化合物C<sub>8</sub>、C<sub>9</sub>、C<sub>11</sub>、C<sub>12</sub>、C<sub>13</sub>对蚜虫的致死率达到80%~100%;C<sub>10</sub>、C<sub>12</sub>、C<sub>15</sub>和C<sub>23</sub>在1000 mg/L时对螨的致死率达到100%。

Table 3 Insecticidal activity of compounds C

Compd	Mortality (%)	
	<i>A. craccivaora</i> (500 mg/L)	<i>T. cinnabarinus</i> (1000 mg/L)
C <sub>8</sub>	89.0	0
C <sub>9</sub>	100	0
C <sub>10</sub>	0	100.0
C <sub>11</sub>	86.2	0
C <sub>12</sub>	100	100.0
C <sub>13</sub>	89.4	0
C <sub>15</sub>	0	100.0
C <sub>23</sub>	0	100.0
C <sub>29</sub>	0	78.4
C <sub>33</sub>	0	61.9
C <sub>35</sub>	11.8	98.0

Note: No insecticidal activity for the compounds which were not listed in the table.

杀菌活性测定结果(表4)显示,C<sub>29</sub>、C<sub>30</sub>和C<sub>31</sub>在500 mg/L时对黄瓜白粉病菌的抑制率均在95%以上。

Table 4 Inhibition rate (%) to *S. fuliginea* of compounds C in different concentration

Compd	500 mg/L	250 mg/L	125 mg/L
C <sub>29</sub>	99.4	94.3	92.5
C <sub>30</sub>	100.0	98.9	95.4
C <sub>31</sub>	95.1	56.1	33.5

Note: No fungicidal activity for the compounds which were not listed in the table.

除草活性测定结果(表 5)表明,C<sub>29</sub>、C<sub>30</sub>、C<sub>31</sub>、

C<sub>33</sub>、C<sub>34</sub>和 C<sub>35</sub>在 100 mg/L 时对马唐的抑制率为 85%~95%。

可以看出,当 NR<sup>1</sup>R<sup>2</sup> 为甲基甲氨基氨基时,均无杀虫、杀菌、除草活性;当 NR<sup>1</sup>R<sup>2</sup> 为二正丁基氨基时,化合物具有较好的杀蚜虫活性;当 NR<sup>1</sup>R<sup>2</sup> 为咪唑基团时,对白粉病菌具有较好的抑制作用;除草活性主要表现为对马唐的抑制作用,其中以 NR<sup>1</sup>R<sup>2</sup> 为二甲基氨基、咪唑基时活性较好。对此将进一步通过 QSAR 进行分析和优化。

Table 5 Herbicidal activity of compounds C (100 mg/L)

Compd	Inhibition rate (shoot/root, %)					
	E. crusgalli	S. vulgare	D. sanguinalis	A. tricolor	C. sativus	B. alboglabra
C <sub>1</sub>	0	45/10	60/0	0	0	0
C <sub>15</sub>	0	0	89/68	52/35	0	0
C <sub>17</sub>	53/20	25/0	90/50	60/50	50/13	60/60
C <sub>22</sub>	0	0	81/11	45/32	0	0
C <sub>23</sub>	0	0	78/24	57/70	0	0
C <sub>25</sub>	0	0	61/19	70/87	0	0
C <sub>27</sub>	0	0	78/85	70/78	0	0
C <sub>29</sub>	88/83	63/83	95/95	88.3/90	62/83	60/70
C <sub>30</sub>	82/85	72/82	95/95	82/75	65/85	65/60
C <sub>31</sub>	75/60	50/75	90/75	95/97	60/75	65/60
C <sub>32</sub>	40/57	6.7/28	65/80	58.3/58.3	38/40	48/30
C <sub>33</sub>	42/0	0	94/90	59/58	0	0
C <sub>34</sub>	66/41	41/8	94/88	52/36	0	0
C <sub>35</sub>	50/15	0	94/90	60/33	0	0

Note: No herbicidal activity for the compounds which were not listed in the table.

致谢:生物活性部分由国家南方农药创制中心(上海)生测部测定,在此深表谢意!

## 参考文献:

- [1] LIU Ai-ping(柳爱平), YAO Jian-ren(姚建仁). 脂醚(酯)农药活性化合物的研究与开发进展 [J]. Chin J Pestic (农药), 2004, 43(5): 196-200.
- [2] ZHANG Yi-bin(张一宾), YANG Hui(杨慧). 具有脂醚结构农药的开发概况及前景 [J]. Jiangsu Pestic (江苏农药), 2002 (2): 8-11.
- [3] SONG Bao-an(宋宝安), LIU Xin-hua(刘新华), YANG Song(杨松), et al. 脂类衍生物的合成与农药生物活性的研究进展 [J]. Chin J Org Chem (有机化学), 2005, 25: 507-525.
- [4] ARMANDO R, SMONE B, ANNALINA L, et al. Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole [J]. J Med Chem, 2002, 45: 4903-4912.

[5] YUAN Li-ping(袁莉萍), CHEN Liang(陈亮), SHEN Zhou(沈宙), et al. 取代苯丙酮肟衍生物及其制备方法和应用: CN, 1640868A [P]. 2004-01-07.

[6] RICHARD M T, RODERICK D F Y. Extended Summaries 9th International Congress of Pesticide Chemistry [J]. Pestic Sci, 1999, 55: 197-218.

[7] WANG Yuan-guang(王远光), YUAN Li-ping(袁莉萍), CHEN Liang(陈亮), et al. 对氯苯丙酮肟衍生物的合成及其生物活性 [J]. Chin J Pestic Sci(农药学学报), 2005, 7(2): 114-118.

[8] LI Zai-feng(李再峰), LUO Fu-ying(罗富英). E, Z-2-(1-咪唑基)-O-(甲基二氯苄基)-2,4-二氯苯乙酮肟硝酸盐的合成与抑菌活性 [J]. Chin J Appl Chem (应用化学), 2001, 18(6): 473-476.

(Ed. JIN SHI HUA)